间充质基质细胞在造血细胞移植中的应用
本文综述间充质基质细胞(MSC)在造血细胞移植中的免疫调节机制与临床应用。MSC通过旁分泌抑制淋巴细胞,宿主巨噬细胞吞噬凋亡MSC参与免疫抑制微环境。主要应用为防治移植物抗宿主病(GVHD),并可能促进造血干细胞植入。日本已批准商业MSC产品用于儿童激素难治性GVHD,加拿大和新西兰附条件批准,美国FDA顾问委员会建议批准。
要点
- MSC通过旁分泌和宿主巨噬细胞吞噬凋亡MSC发挥免疫抑制。
- MSC治疗GVHD的潜在机制包括组织耐受新概念。
- 商业MSC产品已在日本获批用于儿童激素难治性GVHD。
核心结论
- MSC作为辅助细胞治疗在造血细胞移植中具有防治GVHD和促进植入的潜力。
研究设计与样本
- 综述总结历史数据与最新发现,阐述MSC在造血细胞移植中的应用现状。
主要发现
- MSC似通过旁分泌机制(包括分泌介质和代谢调节物)抑制淋巴细胞。
- 宿主巨噬细胞吞噬凋亡MSC是免疫抑制微环境的重要贡献因素。
- 骨髓来源MSC最常研究,但组织来源可能是免疫调节功能的关键决定因素。
- GVHD pathogenesis揭示多个潜在靶点,组织耐受概念提示MSC新机制。
- MSC可能促进造血干细胞植入,在单倍体移植中可能更重要。
关键数值与推荐
- 商业MSC产品在日本获批用于儿童激素难治性GVHD。
- 商业MSC产品在加拿大和新西兰获附条件许可。
- 美国FDA顾问委员会建议批准商业MSC产品。
临床怎么用
- MSC可作为辅助细胞治疗用于防治GVHD,尤其激素难治性儿童GVHD。
- MSC可能促进造血干细胞植入,尤其在单倍体移植中。
局限性
- MSC体内治疗活性机制尚未完全阐明。
- MSC应用仍面临许多挑战和质疑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mesenchymal stromal cells (MSCs) are widely recognized to possess potent immunomodulatory activity, as well as to stimulate repair and regeneration of diseased or damaged tissue. These fundamental properties suggest important applications in hematopoietic cell transplantation. Although the mechanisms of therapeutic activity in vivo are yet to be fully elucidated, MSCs seem to suppress lymphocytes by paracrine mechanisms, including secreted mediators and metabolic modulators. Most recently, host macrophage engulfment of apoptotic MSCs has emerged as an important contributor to the immune suppressive microenvironment. Although bone marrow-derived MSCs are the most commonly studied, the tissue source of MSCs may be a critical determinant of immunomodulatory function. The key application of MSC therapy in hematopoietic cell transplantation is to prevent or treat graft-versus-host disease (GVHD). The pathogenesis of GVHD reveals multiple potential targets. Moreover, the recently proposed concept of tissue tolerance suggests a new possible mechanism of MSC therapy for GVHD. Beyond GVHD, MSCs may facilitate hematopoietic stem cell engraftment, which could gain greater importance with increasing use of haploidentical transplantation. Despite many challenges and much doubt, commercial MSC products for pediatric steroid-refractory GVHD have been licensed in Japan, conditionally licensed in Canada and New Zealand, and have been recommended for approval by an FDA Advisory Committee in the United States. Here, we review key historical data in the context of the most salient recent findings to present the current state of MSCs as adjunct cell therapy in hematopoietic cell transplantation.
引用
- Burnham AJ, Daley-Bauer LP, Horwitz EM, et al. Mesenchymal stromal cells in hematopoietic cell transplantation. Blood Adv. 2020. PMID: 33232479. doi:10.1182/bloodadvances.2020002646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。